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Transcription activator–like (TAL) effector nucleases (TALENs) 
are newly developed programmable nucleases which use a simple 
‘protein–DNA code’ that relates modular DNA-binding TALE repeat 
domains to individual bases in a target binding site. Unlike homing 
endonucleases and zinc figer nucleases (ZFNs), they can be readily 
engineered to bind specific genomic loci, enabling the introduction of 
precise genetic modifications such as gene disruptions, additions, 
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corrections and genome rearrangements. In this thesis, I developed 
improved TALEN architectures to avoid unwanted mutations in genome. 
Then, I carefully chose genome-wide TALEN target sites that did not 
have highly similar sequences elsewhere in the genome and assembled 
TALEN pairs using high throughput Golden Gate cloning system. A 
pilot test including over a hundred pairs of TALENs showed that all 
TALENs were active and disrupted their target genes at high 
frequencies, although two of these TALENs became active only after 
their target sites were partially demethylated using a DNA 
methyltransferase inhibitor. I used the TALEN library to generate 
single- and double-gene knockout cells in which NF-kB signaling 
pathways were disrupted. Compared with cells treated with short 
interfering RNAs (siRNA), these cells showed unambiguous suppression 
of the signal transduction. Furthermore, I developed the TALEN library 
for targeting every exon in protein coding genes of several organisms 
including human. The TALEN library reported here will be broadly 
useful for research and drug discovery.
Keywords : TAL effector nuclease (TALEN), Double-strand breaks 
(DSB), Non-homologous end-joining (NHEJ), Genome engineering. 
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I. Introduction
In the post-genome era, although human genome has been 
sequenced (Lander et al. 2001; Venter et al. 2001), the precise function 
of most genes is still unknown. Hence, one of the most challenging 
tasks in biological research is investigation the function of these genes. 
Important contributions to our understanding of gene functions often 
derive from knockout studies that a specific gene is silenced in cells or 
organisms achieved by gene targeting through homologous 
recombination (HR) (Smithies et al. 1985), an endogenous DNA double 
strand break (DSB) repair mechanism. Although gene targeting is 
widely used in mouse embryonic stem cells to create gene knockout 
animals, the efficiency of HR is extremely low in mammalian and 
other higher eukaryotic cells, ranging from 10-6 to 10-7 (Deng and 
Capecchi 1992). 
In a decade ago, attractive alternative to the above described 
techniques was established, called RNA interference (RNAi). RNAi, 
discovered in the nematode Caenorhabditis elegans, is used to suppress 
the expression of a gene of interest by artificial short interfering RNAs 
(siRNAs) (Fire et al. 1998). Despite of the broad utility of this 
approach in basic research and drug discovery, siRNAs are limited by 
many factors: 1) siRNAs induce gene knockdown rather than gene 
knockout. Thus, small fraction of the activities of target genes remains 
after siRNA treatment (Krueger et al. 2007). 2) siRNAs are not 
specific, displaying sequence dependent off target effects (Jackson et al. 
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2003). Only several nucleotide matches between an siRNA seed 
sequence and the 3’ untranslated region (UTR) of an off target gene 
can trigger suppression of gene expression (Birmingham et al. 2006). 3) 
siRNAs can broadly affect cellular physiology by activating an innate 
immune response and competing with endogenous microRNAs 
(miRNAs) for proteins such as Dicer and the RNA-induced silencing 
complex (RISC), which are critical for miRNA function (Sledz et al. 
2003;Khan et al. 2009). 4) Furthermore, many genes are refractory to 
inhibition via siRNAs (Krueger et al. 2007).
Engineered nucleases such as zinc finger nucleases (ZFNs) 
(Bibikova et al. 2003; Urnov et al. 2005; Doyon et al. 2008; Maeder 
et al. 2008), TAL effector nucleases (TALENs) (Cermak et al. 2011; 
Miller et al. 2011; Sander et al. 2011) and CRISPR/Cas9–based RNA- 
guided endonucleases (RGENs) (Cho et al. 2013; Cong et al. 2013; 
Hwang et al. 2013; Mali et al. 2013), enable the targeted alteration 
precisely at a predetermined locus. These programmable nucleases 
induce site specific DSBs in a genome, which are then repaired by 
endogenous mechanisms that can be exploited to create sequence 
alterations at the cleavage site. ZFNs and TALENs, although they share 
the same FokI-derived nuclease domain, differ in that they employ 
distinctive DNA binding arrays: ZFNs use zinc finger arrays (Kim et 
al. 1996) and TALENs use TAL effector (TALE) repeat arrays (Miller 
et al. 2011). Because these arrays recognize target DNA sequences in a 
modular fashion, tailor-made DNA-binding arrays with desired 
specificities can be constructed by mixing-and-matching pre-characterized 
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modules (Kim et al. 2011).
In this thesis, I described novel TALEN architectures for 
genome engineering using improved fluorescent reporter system (Kim et 
al. 2013b). This TALEN architecture showed high activity at target site 
with 12- to 14-bp spacers comparable with TALEN constructs in 
previous study. And then, to prepare a collection of TALENs that is 
designed to target every protein coding gene in the human genome, I 
developed one-step Golden Gate cloning system to assemble TALEN 
plasmids and computational strategy to search for unique TALEN target 
sites in each gene to avoid potential off target mutations. Nearly 100% 
of TALENs induced site specific mutations at high frequencies. Only 
two TALENs failed to show any measurable mutagenesis activities. 
Each of two TALEN sites was turned out to be heavily methylated. 
With this TALEN library, I generated single- and double-gene knockout 
cells in which NF-κB signaling pathways were disrupted. Furthermore, I 
designed TALEN library for several organisms targeting every exon of 
protein coding genes and showed that almost TALENs were highly 
active. Finally, I investigated difference of mutation signature between 
TALENs and ZFNs. I found that ZFN-induced insertion frequency was 
much higher than the TALEN-induced insertion frequency. From these 
result, the TALEN library resources will be broadly useful for research 
and drug discovery.  
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II. Materials and Methods
1. Dual fluorescent reporter plasmid construction
The amplified product of encoding EGFP sequence from 
pEGFP-N1 using Primer A and B was cloned into the NotI site of the 
pRGS plasmid (Kim et al. 2011). This vector was named pRG2S. 
Oligonucleotides that contained each target sites were synthesized 
(Macrogen, Seoul, South Korea) and annealed in vitro. The annealed 
oligonucleotides were ligated into the vector (pRG2S) digested with 
EcoR1 and BamH1. As previous pRGS plasmid, note that an in-frame 
stop codon should be avoided at the target site either by altering the 
frame or by changing the orientation of the target site. 
2. Cell culture and transfection 
HEK293T/17 (ATCC, CRL-11268) and HeLa cells (ATCC, 
CCL-2) were maintained in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 100 units/mL penicillin, 100 μg/mL 
streptomycin, 0.1 mM nonessential amino acids, and 10% FBS (FBS). 
We transfected 200,000 HEK293 cells using 3 μl of polyethylenimine 
and 1 μg of plasmid DNA in 24-well plates. We transfected 100,000 
HeLa cells with Lipofectamine 2000 (Invitrogen) according to the 
manufacturer's protocol.
3. High-throughput assembly of TALENs
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All steps in TALEN assembly were performed in 96-well 
plates. In each plate, 47 pairs of TALENs were assembled and one pair 
of negative control (FokI vector alone) was included. Our one-step 
Golden-Gate system consisted of 424 TALE array plasmids (6 × 64 
tripartite arrays, 2 × 16 bipartite arrays, and 2 × 4 monopartite arrays). 
For convenience, we numbered each TALE array as follows. We used 
these numbers to choose appropriate arrays to assemble TALEN 
plasmids. 
For example, the half-site sequence, "5'-TGGGGGAGGTGGCG
AGGAAC", can be divided into 8 parts (the first T, GGG, GGA, GGT, 
GGC, GAC, GAA, and the last C). The first T and last C are not 
recognized by TALE arrays. To assemble a TALEN subunit specific to 
this sequence, we chose the following arrays: position1-GGG + 
position2-GGA + position3-GGT + position4-GGC + position5-GAC + 
position6-GAA + the FokI expression vector that contains C-specific 
half-repeat. A detailed protocol is shown below: 
    1) Six TALE array plasmids and a FokI expression vector are 
mixed in each well as follows: 
    1.0 μl TALE array vectors (50ng/μl each) 
    0.5 μl FokI expressing vector (50ng/μl)
    0.5 μl BsaI (New England BioLabs, 10U/μl)
    2.0 μl 10× T4 DNA Ligase Reaction Buffer
    0.1 μl T4 DNA Ligase (New England BioLabs, 2000U/μl)
   10.9 μl ddH2O
 In a 20μl restriction-ligation reaction. 
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    2) The restriction-ligation reaction is carried out in a thermocycler 
as follows:
    37℃ 5 min 〕 → 20 cycles
    16℃ 5 min
    50℃ 15 min
    80℃ 5 min
    3) After the thermocycling reaction, the reaction mixture (6 μl) 
from each well is used for transformation of chemically-competent DH5
α cells (30 μl). Subsequently, cells are inoculated in Flat-Bottom Blocks 
(Qiagen) that are filled with LB medium (800 μl) containing ampicillin 
(50μg/ml). The transformants in 96-well blocks are incubated overnight 
at 37℃ with vigorous shaking.
    4) Two sets of E. coli stocks are prepared by mixing the LB 
culture (50 μl) with 60% glycerol (150 μl); they are separately stored 
at -80℃.
4. Flow cytometry (FACS)
Transfected HEK293T/17 and HeLa cells were trypsinized and 
resus-pended in growth media. Single-cell suspensions were analyzed 
and sorted using the FACSCanto (BD Biosciences). Untransfected cells 
and cells transfected with reporters alone were used as controls.
5. T7E1 assay for mutation detection
HEK293T/17 cells (2x105) pre-cultured in a 24 well plate were 
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transfected with two plasmids encoding a TALEN pair (500ngeach). 
After 72h of incubation, genomicDNA was extracted from the 
transfected cells using the G-dexTM Genomic DNA Extraction Kit 
(iNtRON BIOTECH NOLOGY, Seongnam, S.Korea). Purified genomic 
DNA samples were subjected to the T7E1 assay as described previously 
(Kim et al. 2009). Briefly, genomic region around TALEN target site 
was amplified, melted, and annealed to form heterodupelx DNA. The 
annealed DNA was treated with 5 units of T7E1 endonuclease I (T7E1) 
for 20 min at 37℃. DNA was analyzed by agarose gel electrophoresis. 
PCR primers used for the T7E1 assay in previous study (Kim et al. 
2013b).
6. PCR analysis to detect genomic mutations and 
  sequencing 
Genomic DNA (50 ng per reaction) was subjected to PCR 
analysis using Taq DNA polymerase (GeneAll Biotech, Seoul, Korea) 
and appropriate primers as described in previous study (Kim et al 
2013b). For sequencing analysis, PCR products corresponding to 
genomic rearrangements were purified using the QIAquick Gel 
Extraction Kit (Quiagen, Valencia, CA) and cloned into the T-Blunt 
vector using the T-Blunt PCR Cloning Kit (SolGent, Daejeon, S. 
Korea). Cloned PCR products were sequenced using the M13 primer or 
primers used for PCR amplification.
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7. Analysis and rescue of genome-inactive TALENs
One day before TALEN plasmid transfection, HEK293 cells 
(two million) were pretreated with 0.2 μM 5-aza-dC or 100 ng/ml 
trichostatin A in 24-well plates. After 3 days of incubation, genomic 
DNA was isolated from transfected cells and subjected to the T7E1 
assay. To determine whether the TALEN sites were methylated, 
genomic DNA was treated with bisulfite using the EpiTect Bisulfite kit 
(QIAGEN) according to the manufacturer’s protocol. The 
bisulfite-converted DNA was then amplified using bisulfite-specific 
primers, and the amplified products were subcloned into the T-Blunt 
vector and sequenced.
8. Digital PCR to estimate mutation frequency
Digital PCR analysis was performed based on previous study 
(Lee et al. 2010). Genomic DNA samples were quantified and serially 
diluted with Tris-EDTA buffer. The serially diluted genomic DNA were 
amplified using appropriate primers. The frequencies of mutation were 
calcuated as previous study.
          
9. Gene-knockout cell lines
HEK293T/17 and HeLa cells were co-transfected with TALEN 
plasmids and surrogate reporter plasmids that contain the TALEN target 
site. Gene-knockout cells were enriched by selection as described (Kim 
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et al. 2013a) and cloned by limiting dilution in 96-well plates. 
Typically, cells were maintained for 2 weeks in 96-well plates to 
isolate single clones. These clones were analyzed using T7E1, fPCR 
and dideoxy sequencing.
10. Fluorescent PCR analysis 
Genomic DNA was extracted from each single clones and 
subjected to fluorescence PCR using 5’-carboxyfluorescein-labeled 
primers. Each PCR amplicons were analyzed using an ABI 3730xl 
DNA analyzer. The positions of peaks indicate the lengths of PCR 
products.
11. Episomal reporter assay to detect NF-κB signaling
The NF-κB–dependent firefly luciferase reporter was constructed 
by placing three tandem copies of the NF-κB recognition element 
(TGGGGACTTTCCGC) (Duan et al. 2005) in front of a synthetic 
promoter that consists of the TATA-box and the initiator element. 
Gene-knockout or wild-type cells were co-transfected with the luciferase 
reporter plasmid and the Renilla luciferase plasmid. After 24 h of 
incubation, cells were treated with TNFα (1 ng/ml) or IL-1β (25 ng/ml) 
and incubated for 15 h. Cells were lysed in 1× lysis buffer (100 μl) 




HEK293 knockout clones were lysed and the lysates were 
eletrophoresed on a 7% SDS-PAGE gel. Primary antibodies specific for 
TNFR1 (1:200, Santa cruz biotechnology) or GAPDH (1:200, Santa cruz 
biotechnology) and anti-mouse secondary antibody (1:1000, Santa cruz 





A. Optimization of TAL Effector Nucleases (TALENs)   
1. Dual fluorescent reporter system 
First of all, to measure genome-editing activity of engineered 
nucleases, I developed dual fluorescent reporter system (Figure 1). In 
the previous study, surrogate reporter systems were developed for 
detection of engineered nuclease’s activity and enrichment of mutant 
cells (Kim et al. 2011). The reporter plasmid contains nuclease’s target 
site between the RFP- and GFP- encoding DNA sequences. Because the 
GFP sequence fused to the RFP sequence is out of frame, the cells 
transfected with the reporter plasmid and inactive nuclease-encoding 
plasmid express RFP only. In contrast, functional GFP is expressed 
only when nucleases induce DSBs at target site, whose repair via 
error-prone NHEJ lead to indels that often result in frameshifting 
mutations. Although this system is valuable resource for nuclease 
mediated genome editing, it is limited that only one third of the 
reporter plasmids, which introduced +1 or +2 frameshift, can produce 
in-frame frameshifting. Actually, some active TALENs did not generate 
functional GFP proteins in this reporter system (Figure 2). In this 
regard, I developed improved fluorescence reporter for detecting 
nuclease’s activity by fusing another GFP sequence at the behind of 
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GFP sequence as other frame. Nuclease-mediated indels formation 
generate two different frame shift. The +1 frameshifting mutation makes 
the former GFP protein functional, The +2 frameshifting mutation 
makes latter GFP protein functional. In this dual fluorescent reporter 
assay, TALENs which were inactive in the previous reporter assay were 
highly active (Figure 2). This result showed that dual fluorescent 
reporter system is valuable for detecting engineered nucleases activity.
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Figure 1. Scheme of dual fluorecent reporter-based assay. The reporter 
consists of the mRFP gene, the engineered nuclease’s target sequence 
and the two EGFP genes. mRFP is constitutively expressed by the 
CMV promoter, wheras functional EGFP is not expressed because it is 
out of frame. Nuclease-mediated indel formation in target sites generate 
two different frame shift. The +1 frameshifting mutation makes the 
former GFP protein functional, The +2 frameshifting mutation makes 





Figure 2. Improved results of dual flourescent reporter assay for 
measuring activities of engineered nucleases. (a) Two TALEN pairs 
were not active in RGS reporter assay (Kim et al. 2011). But in other 
frame reporters and RG2S reporters, these TALENs we highly active. 
(b) Target seuquence of TALEN pairs in this assay.
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2. Design of prototype TALENs
In the previous study, TAL effectors fused FokI nuclease 
domain can induce DSBs in human cells and leads to gene disruption 
as ZFNs. Although TALENs are highly active than ZFNs, their broad 
spacer between two TALEN monomer which could induce unwanted 
mutation in genome is barrier for gene therapy or other applications 
(Christian et al. 2010; Li et al. 2011; Miller et al. 2011). To optimize 
the fusion junction between a TALE domain and the FokI nuclease 
domain, I prepared a series of TALE-FokI fusions with different 
junctions by linking each TALE to various amino acid residues in the 
appropriate region of the FokI nuclease domain (Figure 3a). I tested 
these TALE-FokI fusions using the dual reporter system with variable 
spacers between two TALEN monomer binding sites. As the optimized 
TALENs, I chose L4 that showed high activity at target sites with 12- 
to 14-bp spacers but no or negligible activity at sites with < 12-bp or 
> 14-bp spacers (Figure 3b). Compared to the two original TALEN 
constructs that contain additional amino acid residues between the TAL 
effector array and the FokI sequence (S+28 and S+63) (Miller et al. 
2011), L4 TALEN constructs showed nuclease activities at sites with a 




Figure 3. Optimization of TALEN architectures. (a) TALEN target site 
and amino-acid sequences in the fusion junctions that connect the TAL 
effector array to the FokI cleavage domain. (b) Comparison of TALEN 
gene-editing activities. Reporter plasmids that contain target sites with 
variable spacers and TALEN plasmids were co-transfected into HEK293 
cells, and GFP+ cells were counted by flow cytometry. S+28 and S+63 
17
are two prototype TALEN architectures previously reported (Miller et 
al. 2011). Error bars indicated s.e.m. from at least three independent 
experiments.
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B. Human genome-wide TALEN library
1. One-step Golden-Gate cloning system
I developed a one-step Golden-Gate cloning system to assemble 
TALEN plasmids with variable lengths in a high-throughput manner 
(Figure 4). Although Golden-Gate cloning methods have been used for 
the assembly of TALEN plasmids previously (Cermak et al. 2011; Li et 
al. 2011; Morbitzer et al. 2011; Weber et al. 2011; Zhang et al. 2011), 
these methods either rely on the use of PCR, or require gel isolation 
of DNA segments, or require at least two rounds of subcloning steps. 
First of all, I used four TAL effector repeat domains termed NI, NN, 
NG and HD repeat variable di-residues (RVDs), each specific to one of 
the four bases (A, G, T and C, respectively), to make the cloning 
system (Boch et al. 2009; Moscou and Bogdanove 2009). These repeat 
domains consisted of 34 amino acid residues with similar sequences; 
the RVDs at positions 12 and 13 determine the base specificities. Next,  
I designed 64 tripartite-, 16 bipartite- and 4 monopartite- TAL effector 
repeat domain arrays with minimum sequence similarity as following 
criteria; i) removed human’s rare codon (< 10%) and generated ii) 192 
(64 × 3) monopartite with minimum similarity (max. 81.25%), iii) 64 
tripartite, 16 bipartite with minimum similarity in single arrays (max. 
72%). iv) Then, these arrays were subcloned to 6 subgroups via 
PCR-based mutagenesis. Therefore, I prepared a total of 424 TAL 
effector array plasmids (6 × 64 tripartite arrays, 2 × 16 bipartite arrays, 
19
and 2 × 4 monopartite arrays). Then, to make engineered nucleases, I 
prepared 8 obligatory heterodimeric FokI-encoding plasmids (DAS/RR)  
with L4 fusion junction in Figure 3 (Guo et al. 2010). 
20
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Figure 4. Scheme of one-step Golden-Gate cloning system. A total of 
424 TAL effector array plasmids (64 × 6 + 16 × 2 + 4 × 2) (KanR) 
and 8 FokI plasmids (AmpR) are used. One member in each of the six 
positions is chosen; the six arrays are combined with each other for 
subcloning into one of the FokI expression plasmids. This system 
allows construction of TALEN plasmids that contain at least 14.5 (4 
tripartite arrays + 2 monopartite arrays) and up to 18.5 (6 tripartite 
arrays) RVD modules in a single Golden-Gate reaction.
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The TAL effector array plasmids are separated into six 
subgroups in accordance with their positions (Figure 4). When digested 
with BsaI restriction enzyme, each array in a given position generates 
the same four-base pair overhang sequences. TAL effector arrays in 
different subgroups produce different four-base overhang sequences. One 
member in each of the six subgroups is chosen; the six arrays are 
combined with each other for subcloning into one of the FokI 
expression plasmids. This system allows construction of TALEN 
plasmids that contain at least 14.5 (4 tripartite arrays + 2 monopartite 
arrays) and up to 18.5 (6 tripartite arrays) RVDs in a single 
Golden-Gate reaction. The last half-repeat (0.5) is encoded in the FokI 
plasmids. These TALENs recognize DNA sequences of 16–20 bps in 
length, including a conserved base T at the 5′ end. Because TALENs 
function as dimers, these TALEN pairs recognize 32- to 40-bp DNA 
sequences, which consist of two half-sites separated by 12- to 14-bp 
spacers because of L4 fusion junction. This one-step Golden-Gate 
cloning system enables us to TALEN synthesis high-throughput manner 
(Figure 5). 
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Figure 5. High-throughput synthesis of TALENs. High-throughput 
Golden-Gate cloning could process in 96-well plates. Six TAL effector 
array plasmids and one FokI plasmid are mixed in each well. BsaI 
releases the TAL effector arrays and allows an ordered assembly of six 
TAL effector arrays into the FokI plasmid.
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I investigated whether TALEN pairs made by one-step 
Golden-Gate system are functional as TALEN pairs generated by 
modular assembly method. I generated TALEN pair targeting CCR5 
gene as previous study (Kim H.J. 2011) (Figure 6a), and confirmed 
protein expression levels and mutagenesis activity. TALEN pair that 
synthesized by Golden-Gate cloning method (GG-TALEN) was highly 
expressed and induced similarly mutagenesis with TALENs synthesized 
by modular assembly method (MA-TALEN) (Figure 6b, c). And then, I 
constructed 15 TALEN pairs targeting each human genes (Table 1). 
Because longer TALENs are more active (Reyon et al. 2012), I 
designed these TALEN pairs with 18.5 RVD modules. I measured the 
mutagenesis activities of these TALEN pairs in HEK293 cells using 
T7E1 assay. HEK293 cells were transfected with TALEN-encoding 
plasmids, and PCR amplicons from genomic DNA were analyzed by 
T7E1. Mutation frequencies were detected from the intensities of 
cleaved bands relative to intact bands. Mutations were estimated at all 
15 sites at frequencies of 3.9-43% (Figure 7). These pilot tests 
demonstrate that both the new TALEN construct and the one-step 






Figure 6. Validation of TALENs constructed by Golden-Gate assembly. 
(a) TALENs targeted CCR5 in previous study (Kim H.J. 2011) were 
synthesized. (b) Protein expression levels were detected by Western 
blotting. Protein expression of TALEN pairs synthesized by Golden- 
Gate cloning method (GG-TALEN) were comparable with TALEN pairs 
constructed by modular assembly (MA-TALEN). Each numbers are 
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independently synthesized TALENs. (c) T7E1 assay were detected 
endogenous mutagenesis activities of TALEN pairs. GG-TALENs could 
induce mutations in endogenous target sites with high frequency. The 
numbers at the bottom of the gels indicate mutation frequencies 
measured by band intensities
27
Table 1. List of 15 TALEN target sequences in pilot test
28
Figure 7. Pilot test of 15 TALENs. TALEN-mediated mutation 
frequencies were detected using the T7E1 assay. Asterisks indicate the 
expected positions of DNA bands cleaved by T7E1. The numbers at 
the bottom of the gels indicate mutation frequencies measured by band 
intensities.
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2. Design of human genome-wide TALENs
To construct a human TALEN library - a genome-scale 
collection of human gene-targeting TALENs - I obtained the sequences 
of 18,742 protein-coding genes from HUGO Gene Nomenclature 
Committee(Seal et al. 2011) (www.genenames.org) on March 2011 and 
Refseq mRNA database from the National Center for Biotechnology 
Information (Pruitt et al. 2012) (www.ncbi.nlm.nih.gov) on November 
2011. From the coding sequences (CDS) in Refseq mRNA database, we 
searched for candidate TALEN target sites that consist of two half-sites 
of 20-bp in length (18.5RVDs, total 40-bp) separated by 12- or 13-bp 
spacers and that start with the base T and end with A. To identify 
appropriate TALEN target sites for functionally gene disruption, I 
sequentially filtered these sites in the following steps:
1) I removed TALEN target sites that correspond to exon-exon 
junctions.
2) I selected target sites that reside in common exons in cases in 
which genes are expressed in two or more splicing variants
3) I scored the relative positions of target sites in CDS from the 
longest mRNA variant and excluded sites that resided within 
the downstream 30% of each coding sequence.
4) I searched for unique target sequences with the minimum 
number of potential off-target sites in the following manner:
i)    I screened for potential off-target sites in the human 
genome sequence (hg19) by allowing 3-bp mismatches to 
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the left and right half-target sites using Bowtie, an 
ultrafast memory-efficient short read aligner (Langmead et 
al. 2009).
ii)    All sequences were aligned at chromosome loci positions 
for calculating distance between two half-target sites
iii) I excluded candidate sites that are associated with 
potential off-target sites that carry 6 or fewer mismatches. 
I defined potential off-target sites as any homodimeric or 
heterodimeric half-sites separated by 12- to 14-bp spacers. 
As a result, the most homologous potential off-target sites 
carried at least 7-base mismatches with the target site of 
choice.
These criteria were stringent enough to avoid poor sites that were not 
appropriate for site-specific gene knockout but were flexible enough to 
identify multiple sites in most genes (Table 2). 
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Table 2. Pilot test of computational strategy for TALENs design
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Genome-wide search identified at least one TALEN site that 
satisfied all of the criteria described in the text in 17,120 out of 18,742 
genes (91%) (Group A in Table 3). To identify additional target sites, I 
loosened the criteria as follows: 1) I considered TALEN pairs that 
consisted of at least one monomer with 14.5 to 17.5 RVDs (16- to 
19-bp, total 32- to 39-bp) and found 2,842 such sites (Group B) in 
1,361 genes including 162 additional genes. 2) I searched for target 
sites whose potential off-target sites elsewhere in the genome carry at 
least 2-bp mismatches at each of the two half-sites: I identified 706 
sites (Group C) in 393 genes including 338 additional genes. 3) In 
cases in which I failed to find sites that resided within the upstream 
70% of a coding sequence, I searched for TALEN sites that resided 
within the upstream 90%: A total of 270 sites in 154 genes were 
identified (Group D). 4) 60 Genes encode splicing variants that do not 
share a common protein-coding exon. For these genes, I searched for 
sites in exons shared by at least two variants (Group E). 5) Finally, I 
identified 4,582 sites in the remaining 922 genes after I further 
loosened the off-target criterion (Group F). I designed to choose all of 
these additional sites (Groups B to F) preferentially recognized by 18.5 
RVD TALENs with minimum off-target effects. As a result, I identified 
a total of 169,362 TALEN target sites in 18,740 protein-coding genes. I 
couldn’t identify target sites in the rest 2 genes because potential 
TALEN target sites were not exist in their coding sequences. The 
TALEN target sites were designed 9.0 target sites per gene on average. 
The vast majority (98%) of these sites are targeted by 18.5/18.5 RVD 
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TALENs. Of these sites 95% (160,712/169,362) do not have any 
homologous sites with >85% sequence identity (that is, 6-base 
mismatches/ ≤ 40-bp sequence) in the human genome (Table 4).
34
Table 3. Summary of human genome-wide TALEN Library
35
Table 4. Analysis of TALEN target sites in the human genome.
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3. TALEN-mediated genome editing activity
To validate success rate of TAL effector nucleases, I randomly 
chose 478 TALEN pairs that targeted different genes to validate their 
mutagenesis activities in HEK293 cells using dual fluorescent reporter 
assay. As previous study, I measured GFP positive ratio in each 
TALENs by FACS (Kim et al. 2011). Although all of cells transfected 
with reporter plasmid were only <1% GFP positive populations,  472 
of 478 cells (98.7%) transfected with reporter and TALEN-encoding 
plasmids were active (detection limit, ~1%) (Figure 8 and Appendix 1). 
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Figure 8. Reporter-based assay for detecting TALEN activities. HEK293 
cells were co-transfected with the reporter plasmid including appropriate 
target site and TALEN-encoding plasmis. Two days after transfection, 
GFP+ cells were counted by FACS. Almost TALENs were active in 
this reporter assay.
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I investigated whether these active TALENs could, indeed, 
induce mutagenesis in endogenous target sites highly successful as 
reporter assay in HEK293 cells. I selected 104 TALEN pairs in 479 
TALENs and validated their genome editing activities in HEK293 cells 
using T7E1 assay (Figure 9 and Appendix 2). Mutations were detected 
at 101 out of 103 target sites that were successfully PCR-amplified 
(assay sensitivity, ~0.5%). Accordingly, the success rate of our TALENs 
was 98.1%. These TALENs were highly acitive: 78/103 (76%) of 
TALENs were associated with mutation frequencies of >5%, and 57/103 
(55%) of TALENs showed frequencies of >10% (Figure 10). The 
average mutation frequency was 16%. The two best-performing 
TALENs, which were specific to the FKTN and OPN1SW genes, 
induced mutations at frequencies of 54% and 46%, respectively. 
Mutations induced by ten different TALENs were confirmed by DNA 
sequencing (Figure 11). Indels, signatures of error-prone NHEJ repair of 
DSBs, were detected at the target sites. 
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                                                    (continued)
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Figure 9. 103 of TALENs test using the T7E1 assay. The genome-
editing activities of 103 TALENs were measured by the T7E1 assay. 
Asterisks indicate the expected positions of DNA bands cleaved by 
T7E1. The numbers at the bottom of the gels indicate mutation 
frequencies measured by the intensities of cleaved bands. + or – 
indicates the presence or absence of TALENs in transfected cells.
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Figure 10. Distribution of TALEN activities. Detected mutaion 
frequencies by the T7E1 assay were analyzed. These TALENs were 
highly active: 76% (78/103) of TALENs were associated with mutation 
frequencies of >5% (or indel %), and 55% (57/103) of TALENs 
showed frequencies of >10%  
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Figure 11. DNA sequences of indels induced by TALENs. Endogenous 
mutations induced by 10 different TALENs were confirmed by dideoxy 
DNA sequencing. The numbers of inserted or deleted bases are shown 
on the right side of each mutant sequence. WT, wild-type sequence.  
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Furthermore, to know what is the main factors that influenced 
on genome editing frequencies of nucleases, I investigated correlation 
between nuclease mediated episomal reporter activity and endogenous 
mutation activity of 103 TALEN pairs. The estimated values of linear 
(Pearson’s r) and non-linear (Spearman, ρ) correlation coefficients 
between endogenous activities and episomal reporter activities were 0.38 
and 0.44, respectively (Figure 12a, b). This result showed that 
nuclease’s genome editing activity is little correlate with episomal 
reporter based activity. In other words, some endogenous factors such 





Figure 12. Comparison between episomal reporter assay and the T7E1 
assay. The estimated values of linear (Pearson’s r) and non-linear 
(Spearman, ρ) correlation coefficients between endogenous activities and 
episomal reporter activities were 0.38 and 0.44, respectively.
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4. Rescue of inactive TALENs
I investigated why two of the 118 TALENs (including 15 
TALENs used in the pilot study), which were designed to target 
CYP27B1 and FGFR3, failed to show any genome-editing activity in 
the T7E1 assay in contrast with highly active in reporter assay (Figure 
13 and Appendix 1). First, I sequenced the two target sites in HEK293 
cells and found no poly-morphisms or mutations at these sites. Thus, 
the target sites do not contain sequence variations that prevent the 
TALENs from binding. To resolve this unexpected discrepancy in 
cleavage of episomal and chromosomal DNA, I hypothesized that these 
TALENs could not access the endogenous sites owing to the local 
chromatin structure or DNA methylation. To test this idea, I treated 
cells with either trichostatin A, an inhibitor of histone deacetylase 
(HDAC), or 5-aza-2-deoxycytidine (5-aza-dC), an inhibitor of DNA 
methyltransferase. The two TALENs both induced mutations when cells 
were pretreated with the inhibitor of DNA methylation but not with the 
HDAC inhibitor, as shown by the T7E1 assay and by DNA sequencing 
(Figure 14a, c). In addition, bisulfite DNA sequencing analysis revealed 
that all the six CpG dinucleotides in each of the two target sites were, 
indeed, methylated  (Figure 14b). These results showed that TALENs 
cannot recognize heavily methylated DNA and that 5-aza-dC rescued 
the TALENs that did not cleave chromosomal DNA initially, consistent 
with recent biochemical and structural studies (Bultmann et al. 2012; 
Deng et al. 2012; Valton et al. 2012).
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Figure 13. Episomal reporter assays of two genome-inactive TALENs. 
Dual fluorescent reporter assays of two TALENs that could not 
detected mutations by the T7E1 assay. Zif268-FokI (ZFN) was used as 
a positive control. Error bars, means ± s.e.m.
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Figure 14. TALEN-driven mutations in drug-treated cells. (a) I treated 
cells with either trichostatin A, an inhibitor of histone 
deacetylase(HDAC), or 5-aza-2-deoxycytidine (5-aza-dC), an inhibitor of 
DNA methyltransferase. The two TALENs both induced mutations when 
cells were pretreated with the inhibitor of DNA methylation but not 
49
with the HDAC inhibitor, as shown by the T7E1 assay. (b) Cytosine 
methylation at two initially unmodified sites revealed by bisulfite 
sequencing. The DNA sequences of two half-sites and spacers are 
shown in upper case and lower case, respectively. CpG dinucleotides 
are underlined. Closed and open circles indicate methylated and 
unmethylated cytosines, respectively. (c) Sequencing validation of 
TALEN induced mutations in 5-aza-dC treated cells.
50
To avoid treating cell lines with 5-aza-dC, a mutagen, First, I 
synthesized two new TALENs that HD RVD modules replaced with 
NG RVD modules in genome-inactive TALENs for binding methylated 
cytosine as previous study (Deng et al. 2012). The two methylated 
cytosine binding TALENs (mC-TALENs) were rescued mutagenesis 
activity (Figure 15a). Next, I tested whether the two genome-inactive 
TALENs could be replaced with other TALENs that target the same 
gene. I synthesized new TALENs specific to the CYP27B1 and FGFR3 
genes and found that these TALENs were able to induce targeted 




Figure 15. Targeted mutagenesis using alternative sets of TALENs. (a) 
HD RVDs modules in inactive TALENs were replaced with NG RVDs 
and transfected to HEK293 cells. The mutation bands were detected in 
the T7E1 assay. (b) Targeted mutagenesis using a second set of 
TALENs in TALEN library.
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5. Undetectable off-target mutations
Both ZFNs and TALENs can induce mutations at sites other 
than their intended target sites (Gabriel et al. 2011; Hockemeyer et al. 
2011; Mussolino et al. 2011; Pattanayak et al. 2011). As noted above, 
I chose all the TALEN sites carefully to minimize off-target effects. I 
investigated whether my designed TALENs could still induce unintended 
mutations at sites whose sequences are homologous to those of 
on-target sites. I chose ten TALENs that were highly active, showing 
mutation frequencies of 30% or greater (36% on average) at their 
on-target sites, searched for the most likely off-target sites based on the 
sequence homology in the genome, and tested the genome-editing 
activities of these TALENs at these potential off-target sites using the 
T7E1 assay (Table 5). None of these TALENs elicited any measurable 
mutations at their most likely off-target sites (assay sensitivity, ~0.5%), 
demonstrating exquisite specificities of these TALENs (Figure 16).
The specificities of RVDs are not absolute. Among the four 
RVDs, NN appears most promiscuous, as it cannot distinguish G from 
A efficiently (Boch et al. 2009; Moscou and Bogdanove 2009; Miller 
et al. 2011). To address this issue, I searched for additional sites of the 
ten TALENs that would be homologous to the on-target TALEN sites 
if the promiscuity of NN is considered. Nine TALEN sites were not 
associated with any potential off-target sites that carry six or fewer 
mismatches and thus still belong to group A. Only one TALEN site, 
which contained an unusually high number (17) of guanines in the 
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40-bp sequence, was associated with additional off-target sites; in this 
case, there were three potential off-target sites, each of which carries 
6-base mismatches (Table 5). The T7E1 assay showed that this TALEN 
did not induce off-target mutations at these sites (Fugure 16). Among 
the 17,120 group A sites, the vast majority (86%) still satisfy the 
group A criterion when I take the promiscuity of NN into account. As 
expected, the other 14% of the sites contain an unusually high number 
of guanines in their target sequences. These results suggest that we 
would still choose most of the same sites even when I consider the 
promiscuity of NN. Because I designed up to ten sites in each gene, 
potential users who concerned about NN promiscuity may avoid sites 
that contain too many guanines.
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Figure 16. Undetectable off-target mutations with TALENs. (a) The 
genome was searched in silico for potential off-target sites (listed in 
Table 6) of 10 highly active TALENs, and the genome-editing activities 
of TALENs at these sites were tested by the T7E1 assay. Mutation 
frequencies at on-target sites are indicated at the bottom of the gels. 
(b) To account for the promiscuity of the NN RVD, additional sites 
were searched in silico that would be homologous to the on-target sites 
of the 10 highly active TALENs if all adenines were changed to 
guanines in the human genome. Only the PPP1R1B-specific TALEN 
was associated with any potential off-target sites (3 sites, listed in 
Table 6). No mutations were detected at these sites.
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6. TALEN induced genome rearrangement
In many cases, homologous genes are often clustered in a 
chromosome. Many of these homologous genes are redundant in their 
functions. A single gene knockout often fails to cause any phenotypic 
changes owing to these redundancies. I propose that our TALENs could 
be used to induce large chromosomal deletions in a targeted manner to 
remove a cluster of homologous and functionally redundant genes. The 
TALEN library reported here consists of 18,740 TALEN pairs whose 
target sites are distributed all across the human genome. Thus, two 
neighboring TALEN target sites are separated by 170 kbp, on average, 
in a chromosome.
As a proof of principle experiment, I investigated whether and 
how efficiently two TALEN pairs can induce large chromosomal 
deletions in human cell lines. Two combinations of TALEN pairs were 
tested: (i) a BRAF-specific TALEN and a NOBOX-specific TALEN and 
(ii) a EDNRB-specific TALEN and a FGF14-specific TALEN (Figure 
17a). The two target sites of the first pair are separated by 3.6 Mbp 
on chromosome 7, and those of the second pair are separated by 24 
Mbp on chromosome 13. Targeted deletions of these large chromosomal 
segments were detected by PCR and confirmed by DNA sequencing 
(Figure 17b, d). The deletion frequencies measured by limiting dilution 
and PCR detection were 0.6% (BRAF and NOBOX) and 0.4% (EDNRB 
and FGF14) (Figure 17c), which are in line with those obtained with 
ZFNs (Lee et al. 2010). Recently, two TALEN pairs were used to 
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induce a 7-kbp chromosomal deletion within a single gene in porcine 
fibroblasts at a frequency of 10% (Carlson et al. 2012). Apparently, 
large deletions of Mbp by TALENs are at least tenfold less efficient 
than are those of kbp.
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Figure 17. TALEN-mediated targeted genomic deletions. (a) Scheme of 
targeted chromosomal deletions induced by TALENs. Zigzag lines 
indicate TALEN target sites. Small arrows are PCR primers. (b) PCR 
products corresponding to large chromosomal deletions. (c) Deletion 
frequencies measured by dilution PCR. (d) DNA sequences of deletion 
junctions. TALEN recognition sequences are underlined and shown in 
boldface.
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In addition, the large collection of TALENs reported here 
could also be used to induce other types of genome rearrangements, 
which include translocations, inversions, and duplications (Figure 18-20). 
Indeed, I was able to induce these structural variations in a targeted 
manner using various combinations of TALENs at frequencies ranging 
from 0.01% to 0.7. Structural variations in individual human genomes 
contribute to genetic diversity and often are associated with genetic 
diseases and cancer. Although thousands of structural variations have 
been identified, the biological consequences of these variations are 
largely unexplored. Previous studies have reported that the repair of two 
concurrent DSBs in the genome induced by ZFNs gives rise to these 
variations in a targeted manner in cultured human cells (Lee et al. 
2012). To study their functions, one could also use TALENs to induce 
specific variations in cell lines. The high density of our TALENs all 
across the human genome could facilitate the creation of cell lines 
whose genomes are custom-designed. 
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Figure 18. TALEN-mediated targeted genomic inversions. (a) Scheme of 
targeted chromosomal inversions induced by TALENs. Zigzag lines 
indicate TALEN target sites. Small arrows are PCR primers. (b) PCR 
products corresponding to chromosomal inversions. (c) Inversion 
frequencies measured by dilution PCR. (d) DNA sequences of inversion 
junctions. TALEN recognition sequences are underlined and shown in 
boldface.
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Figure 19. TALEN-mediated targeted genomic duplications. (a) Scheme 
of targeted chromosomal duplications induced by TALENs. Zigzag lines 
indicate TALEN target sites. Small arrows are PCR primers. (b) PCR 
products corresponding to chromosomal duplications. (c) Duplication 
frequencies measured by dilution PCR. (d) DNA sequences of 
duplication junctions. TALEN recognition sequences are underlined and 
shown in boldface.
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Figure 20. TALEN-mediated targeted genomic tranlocations. (a) Scheme 
of targeted chromosomal translocations induced by TALENs. Zigzag 
lines indicate TALEN target sites. Small arrows are PCR primers. (b) 
PCR products corresponding to chromosomal translocations. (c) 
Translocation frequencies measured by dilution PCR. (d) DNA 
sequences of translocation junctions. TALEN recognition sequences are 
underlined and shown in boldface.
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C. TALEN-mediated knockout cell lines
1. Establishment of knockout cell lines for NF-κB 
pathway study
To investigate functional gene knockout study in human cells, 
the cell lines, a perpetuating strain of cells in laboratory culture, have 
commonly used. But most model cell lines such as HEK293 cells and 
HeLa cells contain more than three copies of most chromosomes 
(Macville et al. 1999; Bylund et al. 2004). Thus, the disruption of one 
or two alleles does not yield gene-knockout cell lines. In addition, 
some engineered nucleases are cytotoxic (Cornu et al. 2008). Thus, 
cells that contain nuclease-induced mutations often die out, making it 
difficult to isolate rare clonal populations of gene-knockout cells (Kim 
et al. 2009).
As a proof-of-principle experiment for creating gene-knockout 
cells, I used TALENs to disrupt a series of genes associated with NF-κ
B, a transcription factor linked to inflam-mation, septic shock, 
apoptosis, oncogenesis and DNA repair (Perkins 2007; Volcic et al. 
2012). I transfected HEK293 cells or HeLa cells with both TALEN 
plasmids and surrogate reporters, which enabled enrichment of cells in 
which a gene of interest is completely disrupted (Appendix 2) (Kim et 
al. 2011; Kim et al. 2013a). After mutant clones were isolated using 
T7E1 assay, I inspected clonal populations of cells using fluorescent 
PCR for confirming disruption of all alleles that include gene of 
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interests. Gene-knockout cells produced amplicon peaks corresponding to 
indels but not the wild-type peak. Note that all three alleles were 
mutated in a clonal population of cells. DNA sequencing confirmed the 
presence of frameshift mutations at target loci in these cells (Figure 
21). 
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Figure 21. Validation of knockout cell lines. Genotypes of single clones 
were validated by F-PCR and sequencing analyses. TALEN recognition 
sequences are underlined and shown in boldface. The numbers of 
deletions and insertions are indicated. WT, wild-type.
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I searched potential off-target sites that are highly homologous 
to the target site, and no mutations were detected using T7E1 assay 
(Table 6 and Figure 22). And then, to validate that target protein were 
not expressed in gene-knockout cells, I performed western blot analysis 
and RT-PCR (Figure 23a, b). This result showed that these knockout 
clones are functionally gene disruptions without no mutations at other 
potential off-target sites.
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Table 6. Potential off-target sites of TALENs used for knockout cell 
lines
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Figure 22. Undetectable off-target mutations in TALEN-mediated 
knockout cell lines. The top 5 potential off-target sites of TNFR1 and 
IL1R1 TALENs were searched for in silico. The T7E1 assay was used 
to investigate whether these sites were mutated in clonal populations of 





Figure 23. Undetectable gene expression level in gene knockout cells. 
(a) No protein expressions in single- and double-gene-knockouk cells by 
Western blotting. (b) Total RNA was extracted from each knockout cell 
line, and cDNA was synthesized using reverse transcriptase. Target 
mRNA levels were analyzed by PCR using appropriate primers (Kim et 
al. 2013b). GAPDH RNA levels were used as an internal control.
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2. Episomal reporter assay
For the study of NF-κB pathway study with these knockout 
cell lines, I constructed luciferase reporter plasmid that inserted 
multi-copy of p65 binding site in upstream of luciferase gene (Figure 
24). Luciferase was regulated by induction of NF-κB signaling pathway 
such as treatment of tumor necrosis factor alpha (TNFα) or 
interleukin-1 beta (IL-1β), two well-known cytokines that activate NF-κ
B signaling. First, we compared TALEN-mediated gene knockout with 
siRNA-mediated gene knockdown (Figure 25a). Two validated siRNAs, 
each specific to one of the two receptor genes, IL1R1 or TNFR1, only 
partially suppressed the NF-κB signaling by IL-1β or TNFα, 
respectively. Thus, the two cytokines still activated the NF-κ
B-dependent reporter activities in siRNA-transfected wild-type cells, 
compared to cells not treated with cytokines (P < 0.01, Student’s 
t-test). In contrast, both IL1R1 and TNFR1 knockout cells showed 
complete suppression of IL-1β- and TNFα-mediated NF-κB signal 
transduction, respectively. In addition, the two cytokines did not activate 
the luciferase reporter in double-knockout cells in which both IL1R1 
and TNFR1 were disrupted. Transfection of the IL1R1 cDNA into 
IL1R1 knockout cells restored IL-1β-mediated signal transduction, 
demonstrating that the gene-knockout cells were not impaired in NF-κB 
signaling (Figure 25b). Unexpetedly, over-expression of TNFR1 in 
TFNR1 KO cells activated NF-κB-dependent reporters even in the 
absence of TNFα. Similar results have been reported by previous study 
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(Gaeta et al. 2000).
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Figure 24. Schematic of reporter assay related NF-κB signaling. 
Gene-knockout or wild-type cells were co-transfected with the luciferase 
reporter plasmid and the Renilla luciferase plasmid. After 24 h of 
incubation, cells were treated with TNFα or IL-1β and incubated for 15 




Figure 25. Functional assay in knockout cells using reporter.
(a) Comparison of TALEN-mediated gene knockout (KO) with siRNA-
mediated gene knockdown. (b) Transfection of cDNA into 
gene-knockout cells restores cytokine-dependent NF-κB activation. The 
IL1R1 or TNFR1 cDNA was transfected into IL1R1 or TNFR1 knockout 
cells, respectively. Note that the overexpression of the TNFR1 cDNA in 
TNFR1 knockout cells induced NF-κB activation even in the absence of 
TNFα.
77
Next, mitoxantrone (Novantrone), an anti-cancer drug that 
induces nonspecific DSBs in cells, strongly activated the reporter gene 
in the single- and double-gene-knockout cells, demonstrating that NF-κB 
activation triggered by DNA damage is independent of signaling 
through the two cytokines (Figure 26). These gene-knockout cells can 
be used for dissecting NF-κB pathways and screening for reagents or 
factors that selectively modulate NF-κB activation independent of 
signaling via IL-1β or TNFα or both.
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Figure 26. Cytokine-independent NF-κB activation by mitoxantrone. 
Gene-knockout or wild-type cells were co-transfected with the luciferase 
reporter plasmid and the Renilla luciferase plasmid. After 24 h of 
incubation, cells were treated with TNFα/IL-1β/MX and incubated for 
15 h. Cells were lysed and detected luciferase activities.  
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Furthermore, to demonstrate the usefulness of TALEN-mediated 
gene knockout further, we disrupted the NR1H4 and SMEK1 gene in 
HEK293 cells (Figure 27). These genes had been identified as a 
potential mediator of NF-κB activation in a recent genome-wide siRNA 
screen (Gewurz et al. 2012). I prepared knockout cell lines with 
TALENs and surrogate reporters and confirmed by fluorescent PCR and 
Sanger sequencing. Both IL-1β and TNFα strongly activated the 
luciferase reporter gene in three or two independent knockout clones, 
respectively (Figure 28,29). To validate expression level of each genes, 
I performed RT-PCR and It appears that NR1H4 is not expressed even 
in wild-type HEK 293 cells. In case with SMEK1 gene, gene 
expression level was detected in wild-type cells but not detected in two 
independent knockout cell lines. These results showed that these genes 
were a false positive in siRNA screen. 
80
a




Figure 27. Validation of knockout cells related siRNA screening. 
Genotypes of single clones were validated by F-PCR and sequencing 




Figure 28. Invalidation of a false-positive gene identified in a 
genome-wide siRNA screen: NR1H4. (a) NR1H4 gene was not 
expressed in HEK 293 cells. Total RNA was extracted from each 
knockout cell line, and cDNA was synthesized using reverse 
transcriptase. Target mRNA levels were analyzed by PCR using 
appropriate primers. (b) Three independent clones of NR1H4 knockout 
cells were treated with cytokines, and the luciferase reporter activities 
were measured. Error bars indicate S.E.M. from at least three 
independent experiments
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Figure 29. Invalidation of a false-positive gene identified in a genome-
wide siRNA screen: SMEK1. (a) No expression of SMEK1 gene in two 
independent SMEK1 gene-knockout clones.  (b) Two independent clones 
of SMEK1 knockout cells were treated with cytokines, and the 
luciferase reporter activities were measured. Error bars indicate S.E.M. 
from at least three independent experiments.
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D. Expansion of TALEN library
1. Design strategy of TALEN library
In described above, because human genome-wide TALEN 
library was designed for gene disruption, they do not used other 
functional studies such as gene correction, targeted transcript disruption, 
specific cancer related oncogene mutations. For the expanded use of 
TALEN library, I designed TALEN pairs for every exon for human 
protein coding genes. I obtained the DNA sequences of defined human 
protein coding genes from the Ensembl project in April 2013 (Birney 
and Ensembl 2003). Then I developed improved computational strategy 
to identify TALEN target sites in each exon according to the following 
criteria.
1) From the exon sequence database, I identified 40-bp target 
sequences with 12- or 13-bp spacers and start with the base T 
and end with A in each exon.
2) As described above, I searched for unique TALEN target sites 
with the minimum number of potential off-target sites using 
Bowtie preferred without potential methylated sequences. 
3) Then, I comfirmed that the on-target sites indeed exist in 
human genome sequence by searching sequences using Bowtie.
4) To identify additional target sites, I loosened the criteria about 
off-target that mentioned 2). Therefore, I selected TALEN target 
sites with minimum potential off-target sites preferred on-target 
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site alone.
As a result, I designed TALEN target sites for 99.4 % (22,567 
/ 22,693) of genes and 87.8% (541,985 / 617,233) of exons (included 
overlapped exons). I identified a total of 3,242,203 target sites (144 
sites per gene, 6.0 sites per exon on average (Table 7)  
To validate the TALEN mediated mutagenesis activity I 
selected NRAS gene, commonly mutated in myeloid leukemia (Brose et 
al. 2002), and synthesized TALENs targeted every exons in NRAS. 
NRAS gene consists of 7 exons, and I synthesized 6 TALEN pairs 
(exon 6 is too small to design target sites) (Table 8). These TALENs 
were transfected to HeLa cells and I performed T7E1 assay. All 
TALENs could induce targeted mutations with high efficiencies (Figure 
30). 
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Table 7. Summary of TALEN target sites for exons in human protein- 
coding genes.
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Figure 30. TALEN-mediated mutations in each exons of NRAS. (a) 
schematic of NRAS gene. NRAS is consist of 7 exons. (b) Targeted 
mutation in each exons of NRAS were detected by the T7E1 assay. all 
of TALENs were highly active.
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As a proof-of-principle experiment for targeted gene 
modification, I performed TALEN-mediated oncogenic mutations at two 
genes, NRAS and EGFR. Q61K mutation at NRAS gene and L858R 
mutation at EGFR gene are well known for hyperactive oncogenic 
mutations in primary cancers (Brose et al. 2002;Paez et al. 2004). With 
designed TALEN pairs targeting NRAS and EGFR with appropriate 
ssODN contained PstI and HindIII respectively, I transfected human 
K562 cells. PCR amplicons of these chromosomal regions were partially 
digested by appropriate restriction enzymes, demonstrating ~5% 
genome-editing efficiency (Figure 31a). I determined the DNA 
sequences of PCR products representing the targeted genomic regions 





Figure 31. TALEN-mediated homology depenent rapair (HDR). (a) HDR 
mediated gene-editing in NRAS and EGFR. TALENs and ssODN 
including each PstI and HindII restriction enzymes, respectively were 
transfected to K562 cells and after 3 d of incubation, genomic DNA 
was isolated, and the target locus was amplified with appropriate 
primers. TALEN with ssODN-mediated mutations were detected 
appropriate restriction enzyme treatment. (b) sequence analysis of 
targeted modifications.
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2. TALEN library for several organisms
TALENs are also applicable for several organisms such as 
mouse, rat, zebrafish and C. elegans. In the previous studies, TALENs 
have been successfully used for making gene-knockout animals and 
plants. Therefore, as human TALEN library, I designed TALENs 
targeting protein coding genes for mouse, rat, zebrafish and C. elegans 
(Table 9).
To validate these designed TALENs, I synthesized TALEN 
pairs targeting several genes in zebrasifh (Table 10). Then TALENs 
transcripts were injected to zebrafish’s embryo and performed T7E1 
assay to detect mutagenesis activities. The TALEN pairs were highly 
active from 10 to 50 % of populations as results of TALENs for 
human genes (Figure 32). I verified the TALEN induced mutation 
sequences by dedeoxy sequencing (Figure 33). These result showed that 
TALEN libraries for several organisms are useful tools for gene editing. 
The TALEN library reported here provides a foundation for functional 
genomic studies.
92
Table 9. Summary of TALEN library for several organisms
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Table 10. List of TALEN target sites for zebrafish
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Figure 32. TALEN-mediated gene disruption in zebrafish. TALEN-
encoding mRNAs were injected zebtrafish embryos and after 1 d 
incubation, genomic DNA was extracted from pools of 8 embryos. 
TALEN induced mutations were detected by the T7E1 assay. each 
numbers of genes indicated independent pools of embryos.
95
Figure 33. Sequencing validation of TALEN-induced indels in zebrafish.
Endogenous mutations induced by 10 different TALENs were confirmed 
by dideoxy DNA sequencing. The numbers of inserted or deleted bases 
are shown on the right side of each mutant sequence. WT, wild-type 
sequence.  
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E. Comparison of TALENs and ZFNs
TALENs and ZFNs share the same FokI nuclease domain and 
induce site-specific DNA cleavages, whose repair via error-prone NHEJ 
gives rise to indels at the target sites. I investigated difference of 
TALENs with ZFNs in patterns of mutations (Kim et al. 2013c). 
First, I compared mutation signatures of ZFNs and TALENs 
that have been reported in the literature. I calculated frequencies of 
insertions, deletions, and complex patterns that accompany both 
insertions and deletions at each target site in the following categories: 
mammalian cells, mammalian organisms, non-mammalian animals, and 
plants. my analysis included a total of 1,456 mutant sequences at 122 
target sites reported in 43 independent studies (Figure 34). ZFN-induced 
mutations are much more evenly distributed between deletions and 
insertions in any organism or cell line than are TALEN-induced 
mutations. In particular, insertions are rarely obtained with TALENs. 
For example, ZFNs induce insertions in mammalian cells at a frequency 
of 43%, comparable to that of deletions (52%). In sharp contrast, 
TALENs induce insertions at a frequency of 1.6%, much lower than 
that of deletions (89%). In all other systems combined, the 
ZFN-induced insertion frequency is much higher than the 
TALEN-induced insertion frequency (24% vs. 4.1%) (Student’s t-test, P 
< 0.05). I also found that ZFNs are associated with lower deletion 
frequencies (59%) as compared to TALENs (81%) (P < 0.05). Complex 
patterns are obtained at comparable frequencies (17% with ZFNs and 
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15% with TALENs). 
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Figure 34. ZFN and TALEN mutation patterns reporterd in the 
literature. Nuclease-induce mutant sequences were classified as three 
different type: insertions, deletions or comlex (that is, having both 
insertions and deletions) patterns. The number of mutant events is 
shown above each other.
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Next, I investigated that pattern of TALENs induced mutations 
different with that of ZFNs by several TALENs and ZFNs whose target 
sites overlap with each other (Figure 35). I transfected HEK 293 cells 
with them, and compared mutation patterns using Sanger sequencing 
methods. In line with my analysis described above, TALENs, unlike 
ZFNs, rarely produced insertions. Thus, five TALENs induced insertions 
at an overall frequency of 2.6%. In sharp contrast, ZFNs induced 
insertions much more frequently (39%) (P < 0.05) (Figure 36). This 
results showed that the differential mutation signatures induced by 
TALENs and ZFNs do not arise from the differences in target loci. 
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Figure 35. Overlapping target sites of ZFNs and TALENs. Both the left 
and right half-sites are underlined. Spacers are shown in small latters.
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Figure 36. Comparison of ZFNs and TALENs that target overlapping 
sites. Nuclease-induce mutant sequences were classified as three 
different type: insertions, deletions or comlex (that is, having both 
insertions and deletions) patterns. The number of mutant events is 
shown above each other.
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Furthermore, I investigated the molecular basis of the difference 
in mutation patterns. I hypothesized that the larger spacers (12 to 21 
bp) in the TALEN sites as compared to the ZFN sites (mostly 5 to 6 
bp) might cause the difference. To test this idea, I expressed two 
homodimeric ZFNs in cells whose genome was modified to contain 
ZFN sites with 15-bp spacers (Figure 37a). Unlike ZFNs that target 
sites with 5- to 6-bp spacers, these ZFNs produced insertions much less 
frequently than deletions (1.8% vs. 86%) (Figure 37b). I speculated that 
the larger spacers either in ZFN sites or in TALEN sites may give rise 
to heterogeneous overhangs when cleaved by nucleases. In contrast, 
ZFNs that target sites with 5- to 6-bp spacers produce defined 4- or 
5-bp overhangs, which might be efficiently filled in before ligation to 
yield insertions. Defined overhangs may facilitate targeted insertions of 
plasmid DNA at genomic sites (Maresca et al. 2013).
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Figure 37. Mutations induced by ZFNs with 15-bp spacer. (a) I 
modified the CCR5 target site of ZFN-224 by cotransfecting K562 cells 
with ZFN-224 plasmids and oligonucleotides as described previous study 
(Chen et al. 2010). The two monomers that constitute ZFN-224 were 
used as homodimers to cleave the modified sites with 15-bp spacers. 
Sequences recognized by ZFNs are underlined. Spacers are shown in 




The TALEN technology has recently developed, which can be 
rationally designed de novo due to its highly predictable modularity. 
Unlike ZFNs, which have sequence-bias toward guanine-rich sites 
(Maeder et al. 2008), TALENs have no sequence-bias toward any base 
and, thus, can be designed to target any sequence. 
Over the last two years, TALENs have been reported for 
genome editing in yeast (Li et al. 2011), roundworm (Wood et al. 
2011), fruitfly (Liu et al. 2012), cricket (Watanabe et al. 2012), 
zebrafish (Huang et al. 2011;Sander et al. 2011;Bedell et al. 2012), 
frog (Lei et al. 2012), mouse (Sung et al. 2013), rat (Tesson et al. 
2011), pig (Carlson et al. 2012), cow (Carlson et al. 2012), thale cress 
(Cermak et al. 2011), rice (Li et al. 2012), silkworm (Ma et al. 2012) 
and human cells (Hockemeyer et al. 2011;Miller et al. 2011;Reyon et 
al. 2012;Kim et al. 2013b). Although previous TALEN architectures are 
highly active with high success rates, for genome-scale study, they are 
limited some aspects. 1) The success rates of TALEN-mediated gene 
disruption range from 64% to 88% in mammalian cells (Cade et al. 
2012;Carlson et al. 2012;Reyon et al. 2012). These success rates are 
certainly impressive compared to those achieved with ZFNs. On a 
genomic scale about 20,000 genes, however, failure rates of 12–36% 
correspond to 2,000–7,000 genes, if one TALEN is used per gene. 2) 
The previous TALEN architectures have poorly defined fusion junctions 
between TAL effectors and FokI cleavage domain (Christian et al. 
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2010;Li et al. 2011;Miller et al. 2011). Different with ZFNs that have 
a narrow range of spacers (5- to 6-bp) (Kim et al. 2009), these 
TALEN constructs induce mutagenesis in broad spacers (12- to 22-bp) 
that may induce indels at unwanted loci in genome.
To this end, I developed TALEN architectures with 12- to 
14-bp spacers that might reduce unwanted mutations in genome. 
Furthermore, using obligatory heterodimeric FokI nuclease domains, the 
TALEN constructs were improved target specificities through elimination 
of TALEN monomer’s homodimeric activity. And my thesis suggested 
that a nearly 100% success rate could be achieved with TALENs by 
avoiding heavily methylated sites, making it feasible to initiate 
genome-scale gene-knockout studies. This high success rates were 
important for TALEN mediated genome scale study. 
I developed a scalable Golden-Gate assembly system that 
consists of a total of 432 plasmids (424 TAL effector array plasmids 
and 8 FokI plasmids) and used this system to construct a TALEN 
library, a collection of 18,740 TALEN pairs, to disrupt or modify every 
protein-coding gene in the human genome. Recently, two different solid 
surface–based assembly methods for the synthesis of TALEN plasmids 
were reported: iterative capped assembly and fast ligation-based 
automatable solid-phase high-throughput (FLASH) systems (Briggs et al. 
2012;Reyon et al. 2012). Although these methods can be automated at 
least partially, multiple cycles of ligation and washing steps in addition 
to PCR are involved before subcloning into an expression vector. 
Furthermore, FLASH uses up to microgram quantities of TAL effector 
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array plasmids in each reaction, making it cost-inefficient and 
cumbersome to scale up. Compared to these methods, My Golden-Gate 
cloning system allowed PCR-free TALEN assembly with much less 
hands-on time and greatly reduced plasmid quantities. In addition, 
cloning efficiency was higher in general with Golden-Gate systems than 
with solid surface–based methods. 
The one-step Golden-Gate cloning systems can use several 
other applications of TAL effectors. The DNA sequence based binding 
protein is valuable resource for targeted gene regulation by fusing VP64 
activation domain or KRAB repression domain (Maeder et al. 2013b; 
Perez-Pinera et al. 2013). TAL effectors fused histone 
demethlytransferase are also useful options for targeted gene regulations 
(Maeder et al. 2013a). These gene regulators enable the gain of 
function studies. In addition, because they are not induced permanent 
gene modifications like engineered nucleases, they can be used for 
transient or inducible gene regulations. TAL effector’s random or target 
library pools also can used phenotype screening as zinc finger protein 
library.   
TAL effectors also can be used targeted chromosomal 
visualizers to combine with fluorescent proteins (Miyanari et al. 2013). 
Unlike other chromosomal visualizers such as FISH that need fixed 
cells by chemicals and only processed in death cells, TALE fluorescent 
visualizers enable to detect target sequences in living cells. So, they 
can use to detect the shape and loci of targeted chromosomes during 
the cell cycles. 
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Then, I established computational strategy for TALENs 
targeting almost protein coding gens in several organisms. As described 
results above, I identified 40-bp target sequences with 12- or 13-bp 
spacers in each gene, which were recognized by TALEN pairs that 
consist of two 18.5 RVDs with the minimum number of potential 
off-target sites. The ten of TALENs that were highly active at their 
on-target sites, did not induce any measurable mutations at their most 
likely off-target sites.
In the short term, TALEN-mediated gene-knockout experiments 
should be useful for validating or invalidating the functions of genes 
identified by genome-scale siRNA library screens, which have revealed 
many potential drug targets associated with various diseases (Sigoillot 
and King 2011). Unfortunately, many of the newly identified genes 
have turned out to be false positives that resulted from off-target effects 
(Lin et al. 2005;Adamson et al. 2012). To distinguish true positives 
from false positives, one could use TALENs to knock out candidate 
genes as demonstrated here, rather than using another siRNA to 
downregulate the genes. In the long term, TALENs could enable the 
creation of a series of cell lines in which a family of druggable target 
genes encoding proteases, kinases, phosphodiesterases and G protein–
coupled receptors are disrupted. In principle, genetic screens can be 
performed using these cell lines instead of siRNA libraries. The 
TALEN library reported here provides a foundation for functional 
genomic studies based on gene knockout rather than knockdown in 
mammalian cells.
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Furthermore, the TALEN pairs in advanced libraries for every 
exon in protein coding genes of several organisms can be used to 
generate not only gene disruption, but also precise genetic modifications 
by homology directed repair. For example, as described above, single  
nucleotide changes can be made in a gene of interest to study 
phenotypic differences associated with single nucleotide polymorphisms 
in an otherwise isogenic background. A reporter gene can be fused to a 
gene of interest to monitor the expression of the gene or to track the 
protein. 
Although the primary use of my TALENs in drug discovery 
will be to identify and validate druggable target genes, I envision that 
some TALENs or their inproved versions would be useful 
therapeutically themselves. An example for a targeted nuclease that is 
in clinical trials in Sangamo’s CCR5-specific ZFN for the treatment of 
AIDS, whish is now under clinical investigation in the United States 
(Holt et al, 2010).  TALENs can also be used to disrupt 
disease-associated genes or correct genetic defects in stem and somatic 
cells. I propose that the one-step Golden-Gate cloning system and 
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TALEN은 최근에 새롭게 개발된 유 자 가 로 DNA 의 염
기를 하나씩 특이 으로 인식하는 TALE을 이용한다. 특히 TALEN
은 기존의 유 자 가 보다 쉽게 제작할 수 있고 유 자 변이 효율
도 상당히 개선되어 다양한 동·식물에 응용되고 있다. 이번 연구에
서는 기존의 TALEN의 구조를 개선해 게놈 상에 원치 않는 곳에 변
이를 일으킬 가능성을 다. 그리고 컴퓨터 로그래 을 통하여
인간 체의 유 자에 해, 게놈 상에 유사한 염기서열이 거의 없
는 TALEN 염기서열을 선별했다. 선별된 TALEN 서열에
해 TALEN을 쉽게 만들 수 있는 고속 량 합성법을 개발하 다. 
이를 통해 100여개 이상의 유 자를 하는 TALEN을 만들었고
실제 변이를 유도한 결과 거의 모든 TALEN이 높은 효율로 유 자
변이를 일으켰다. 변이를 유도하지 못한 두 TALEN의 서열을
분석한 결과, 시토신이 메틸화되어 있었으며 이로 인해 TALEN이
작동하지 못했음을 알 수 있었다. 한 이 TALEN을 이용하여 유
자 변이가 유도된 세포주를 건립하 으며 실제 유 자의 기능이 없
어졌음을 확인했다. 이러한 유 자 녹아웃은 기존의 siRNA를 이용
하는 방법보다 매우 효율 으로 완벽히 유 자의 기능을 상실시키
는 확인했다. 나아가 인간뿐만 아니라, 다양한 실험동물들에 해
TALEN 서열을 미리 선별해 놓음으로써 신약개발 등의 다양한
연구에 리 활용될 수 있을 것으로 생각한다.  
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